SLC2A1 and colorectal carcinoma: Knockdown of KLK10 inhibits glucose metabolism and cell proliferation [92], suggesting that targeting KLK10 could downregulate GLUT1 via the PI3K/AKT/mTOR pathway, thereby inhibiting CRC growth [93].